172 related articles for article (PubMed ID: 34766620)
1. Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics.
Ramsden D; Belair DG; Agarwal S; Andersson P; Humphreys S; Dalmas DA; Stahl SH; Maclauchlin C; Cichocki JA
ALTEX; 2022; 39(2):273–296. PubMed ID: 34766620
[TBL] [Abstract][Full Text] [Related]
2. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
[TBL] [Abstract][Full Text] [Related]
3. Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.
Hirabayashi Y; Maki K; Kinoshita K; Nakazawa T; Obika S; Naota M; Watanabe K; Suzuki M; Arato T; Fujisaka A; Fueki O; Ito K; Onodera H
Nucleic Acid Ther; 2021 Apr; 31(2):114-125. PubMed ID: 33470890
[TBL] [Abstract][Full Text] [Related]
4. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications.
Fabre K; Berridge B; Proctor WR; Ralston S; Will Y; Baran SW; Yoder G; Van Vleet TR
Lab Chip; 2020 Mar; 20(6):1049-1057. PubMed ID: 32073020
[TBL] [Abstract][Full Text] [Related]
5. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
Qu Y; Henderson KA; Harper TA; Vargas HM
Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
[TBL] [Abstract][Full Text] [Related]
6. Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization.
Fowler S; Chen WLK; Duignan DB; Gupta A; Hariparsad N; Kenny JR; Lai WG; Liras J; Phillips JA; Gan J
Lab Chip; 2020 Feb; 20(3):446-467. PubMed ID: 31932816
[TBL] [Abstract][Full Text] [Related]
7. The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases.
Paul D; Miller MH; Born J; Samaddar S; Ni H; Avila H; Krishnamurthy VR; Thirunavukkarasu K
Expert Opin Drug Discov; 2023 Feb; 18(2):193-206. PubMed ID: 36562410
[TBL] [Abstract][Full Text] [Related]
8. Application of microphysiological systems for nonclinical evaluation of cell therapies.
Candarlioglu P; Delsing L; Gauthier L; Lewis L; Papadopoulos G; Freag M; Chan TS; Homan K; Fellows MD; Pointon A; Kojala K
ALTEX; 2024 May; ():. PubMed ID: 38746991
[TBL] [Abstract][Full Text] [Related]
9. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
[TBL] [Abstract][Full Text] [Related]
10. Meeting report: oligonucleotide ADME workshop.
Hood S; Kenworthy D; Christensen JK
Xenobiotica; 2022 Aug; 52(8):957-961. PubMed ID: 36093882
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate).
Baran SW; Brown PC; Baudy AR; Fitzpatrick SC; Frantz C; Fullerton A; Gan J; Hardwick RN; Hillgren KM; Kopec AK; Liras JL; Mendrick DL; Nagao R; Proctor WR; Ramsden D; Ribeiro AJS; Stresser D; Sung KE; Sura R; Tetsuka K; Tomlinson L; Van Vleet T; Wagoner MP; Wang Q; Arslan SY; Yoder G; Ekert JE
ALTEX; 2022; 39(2):297–314. PubMed ID: 35064273
[TBL] [Abstract][Full Text] [Related]
12. Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry.
Baudy AR; Otieno MA; Hewitt P; Gan J; Roth A; Keller D; Sura R; Van Vleet TR; Proctor WR
Lab Chip; 2020 Jan; 20(2):215-225. PubMed ID: 31799979
[TBL] [Abstract][Full Text] [Related]
13. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.
Kopec AK; Yokokawa R; Khan N; Horii I; Finley JE; Bono CP; Donovan C; Roy J; Harney J; Burdick AD; Jessen B; Lu S; Collinge M; Sadeghian RB; Derzi M; Tomlinson L; Burkhardt JE
J Toxicol Sci; 2021; 46(3):99-114. PubMed ID: 33642521
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.
Rubiano A; Indapurkar A; Yokosawa R; Miedzik A; Rosenzweig B; Arefin A; Moulin CM; Dame K; Hartman N; Volpe DA; Matta MK; Hughes DJ; Strauss DG; Kostrzewski T; Ribeiro AJS
Clin Transl Sci; 2021 May; 14(3):1049-1061. PubMed ID: 33382907
[TBL] [Abstract][Full Text] [Related]
15. Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.
Watson DE; Hunziker R; Wikswo JP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1559-1572. PubMed ID: 29065799
[TBL] [Abstract][Full Text] [Related]
16. Diffusion Behavior of Differently Charged Molecules in Self-Assembled Organic Nanotubes Studied Using Imaging Fluorescence Correlation Spectroscopy.
Ghimire G; Espinoza R; Xu H; Nagasaka S; Kameta N; Masuda M; Higgins DA; Ito T
Langmuir; 2019 Jun; 35(24):7783-7790. PubMed ID: 31125237
[TBL] [Abstract][Full Text] [Related]
17. Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs.
Thibonnier M; Ghosh S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108289
[TBL] [Abstract][Full Text] [Related]
18. Higher lung accumulation of intravenously injected organic nanotubes.
Maitani Y; Nakamura Y; Kon M; Sanada E; Sumiyoshi K; Fujine N; Asakawa M; Kogiso M; Shimizu T
Int J Nanomedicine; 2013; 8():315-23. PubMed ID: 23345977
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.
Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP
Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790
[TBL] [Abstract][Full Text] [Related]
20. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.
Ewart L; Dehne EM; Fabre K; Gibbs S; Hickman J; Hornberg E; Ingelman-Sundberg M; Jang KJ; Jones DR; Lauschke VM; Marx U; Mettetal JT; Pointon A; Williams D; Zimmermann WH; Newham P
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():65-82. PubMed ID: 29029591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
